Rapid Adoption of Advanced Diagnostics
The rapid adoption of the numerous number of innovative IVD methods such as digital PCR, mass spectrophotometry, chromosome analysis, tissue microarrays, next gen sequencing and cell signaling pathway testing are currently driving the growth of the market. In the next-generation sequencing based IVDs, several sequencing-based diagnostic tests and test services have been recently launched, including Althea Diagnostics’ BRAF mutations test, Sequenta’s LymphoSIGHT, and Enzo’s MultiGEN multiplex DNA sequencing.
The increasing incidences of the chronic and infectious diseases, rise in the geriatric population are also the some of the factors which drives the IVD market in Canada region. Furthermore, the increase in the investments for the advancement of healthcare sector by the government is also anticipated to boost the growth of the market.
Opportunities arising from increasing investment in the sector
The common trend that is being observed here is that the leading players are acquiring the smaller technological companies to produce the companion diagnostic tests; while the pharmaceutical companies, attracted by the opportunities in the IVD market, both are investing and collaborating with diagnostic devices companies to extend their drugs market after major patent expirations. Roche Diagnostics and Abbott Laboratories are an example of the major companies in the market, which focus on achieving the synergy between their diagnostic solutions and pharmaceutical solutions.
Some of the factors are the lack of proper reimbursements policies and stringent regulatory framework which are also limiting the growth of the market.
Canada becomes the leading market
Canada is the gradually becoming the market leader for both globally and North America. Canada is the next biggest market in the North America region for the in-vitro diagnostics. This is due to the advances on the technology forefront and the higher GDP of the nation. This growth is developing the need to analyze, review and forecast the growth of the In-Vitro Diagnostics market.
Key Developments in the Market
- September, 2016: Thermo Fisher Scientific completes the acquisition of FEI Company
- August, 2016: Thermo Fisher Scientific partners with Hamilton Bonaduz AG to accelerate automation platforms access for forensic customers.
- September, 2016: Roche announced the launch of its DISCOVERY 5-Plex procedure and reagents for immunohistochemistry (IHC) research applications. It is the first pre-optimized, fully automated multiplex procedure available on the VENTANA DISCOVERY ULTRA2 instrument.
Reasons to Purchase this Report
- Current and future Canada in vitro diagnostics market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet in excel.
This report can be customized to meet your requirements..
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER'S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING INCIDENCES OF CHRONIC DISEASES
6.1.2 INCREASING GOVERNMENT HEALHTCARE EXPENDITURE AND CONSUMER'S HEALTHCARE SPENDING
6.1.3 RAPID ADOPTION OF POINT OF CARE TESTING
6.2 MARKET RESTRAINTS
6.2.1 UNFAVORABLE REIMBURSEMENT POLICIES
6.2.2 STRINGENT REGULATORY FRAMEWORK
6.4 KEY CHALLENGES
7. Market Segmentation
7.1 SEGMENTATION-BY TECHNIQUE
7.1.1 CLINICAL CHEMISTRY
7.1.3 POINT OF CARE DIAGNOSTICS
7.1.4 MOLECULAR DIAGNOSTICS
7.2 BY TYPE OF PRODUCT
7.2.3 DATA MANAGEMENT SYSTEMS
7.3 BY APPLICATIONS
7.4 BY END USER
7.4.2 HOSPITALS & LABORATORIES
7.4.3 PHARMACEUTICAL & BIOTECHNOLOGY
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 ABBOTT LABORATORIES, INC.
9.2 JOHNSON & JOHNSON
9.3 BECTON, DICKSON AND COMPANY
9.4 DANAHER CORPORATION
9.5 THERMO FISHER SCIENTIFIC, INC.
9.6 BIO-RAD LABORATORIES, INC.
9.7 ALERE, INC.
9.8 ROCHE DIAGNOSTICS LIMITED
9.9 SIEMENS HEALTHCARE
10. FUTURE OF THE MARKET
- ABBOTT LABORATORIES Inc.
- JOHNSON & JOHNSON
- DICKSON AND COMPANY
- DANAHER CORPORATION
- THERMO FISHER SCIENTIFIC Inc.
- BIO-RAD LABORATORIES Inc.
- ALERE Inc.
- ROCHE DIAGNOSTICS LIMITED
- SIEMENS HEALTHCARE.